{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluorouracil+%285-FU%29&page=23", "query": { "intervention": "Fluorouracil (5-FU)", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 1032, "total_pages": 104, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluorouracil+%285-FU%29&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluorouracil+%285-FU%29&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T17:48:49.917Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00324415", "title": "Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 45, "start_date": "2006-09", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2025-05-30", "last_synced_at": "2026-10-16T17:48:49.917Z", "location_count": 7, "location_summary": "La Jolla, California • Los Angeles, California • Boston, Massachusetts + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324415" }, { "nct_id": "NCT02705352", "title": "5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ectropion", "Skin Neoplasms" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Normal saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts Eye and Ear Infirmary", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 1, "start_date": "2016-08-25", "completion_date": "2019-01-25", "has_results": true, "last_update_posted_date": "2020-03-09", "last_synced_at": "2026-10-16T17:48:49.917Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02705352" }, { "nct_id": "NCT00016978", "title": "Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2001-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-05", "last_synced_at": "2026-10-16T17:48:49.917Z", "location_count": 23, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 19 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Cedar Rapids", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016978" }, { "nct_id": "NCT06780111", "title": "Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "I-DXd", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 298, "start_date": "2025-07-30", "completion_date": "2032-01-04", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-16T17:48:49.917Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06780111" }, { "nct_id": "NCT03690921", "title": "Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Canal Squamous Cell Carcinoma", "Stage I Anal Cancer AJCC v8", "Stage II Anal Cancer AJCC v8", "Stage IIA Anal Cancer AJCC v8", "Stage IIB Anal Cancer AJCC v8", "Stage III Anal Cancer AJCC v8", "Stage IIIA Anal Cancer AJCC v8", "Stage IIIB Anal Cancer AJCC v8", "Stage IIIC Anal Cancer AJCC v8" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy", "type": "RADIATION" }, { "name": "Quality-of-Life Assessment", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 8, "start_date": "2018-11-08", "completion_date": "2022-06-03", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-10-16T17:48:49.917Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03690921" }, { "nct_id": "NCT02405585", "title": "Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Carcinoma Non-resectable" ], "interventions": [ { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "Algenpantucel-L Immunotherapy", "type": "BIOLOGICAL" }, { "name": "SBRT", "type": "RADIATION" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-04", "completion_date": "2016-07-30", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-10-16T17:48:49.917Z", "location_count": 4, "location_summary": "Louisville, Kentucky • Burlington, Massachusetts • Albuquerque, New Mexico + 1 more", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02405585" }, { "nct_id": "NCT01128387", "title": "Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2010-05", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-10-16T17:48:49.917Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01128387" }, { "nct_id": "NCT01561014", "title": "Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Esophagus", "Adenocarcinoma of the Gastroesophageal Junction", "Adenocarcinoma of the Stomach", "Squamous Cell Carcinoma of the Esophagus", "Stage II Esophageal Cancer", "Stage II Gastric Cancer", "Stage III Esophageal Cancer", "Stage III Gastric Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "PROCEDURE" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER", "GENETIC" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2007-04", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-10-16T17:48:49.917Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01561014" }, { "nct_id": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Adenocarcinoma", "HER2 Gene Mutation" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Nutrition questionnaires (optional)", "type": "OTHER" }, { "name": "stool and saliva samples (optional)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2024-02-01", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-16T17:48:49.917Z", "location_count": 10, "location_summary": "Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06123338" }, { "nct_id": "NCT06792695", "title": "A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Volrustomig", "type": "DRUG" }, { "name": "FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 80, "start_date": "2025-03-12", "completion_date": "2028-09-29", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-16T17:48:49.917Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06792695" } ] }